A leading melanoma medical oncologist, Dr. Michael Postow is known for his contributions to both patient care and scientific advancement. After completing his undergraduate studies in biology at Duke University, he pursued his medical degree at New York University School of Medicine, where he graduated summa cum laude and was named valedictorian. Dr. Michael Postow trained in internal medicine at Brigham and Women’s Hospital/Harvard Medical School before specializing in medical oncology at Memorial Sloan Kettering Cancer Center (MSK). He completed his fellowship there and served as Chief Fellow before joining the faculty.
At MSK, Dr. Michael Postow is Chief, Melanoma Service and co-director of the Melanoma Disease Management Team. He specializes in the treatment of patients with advanced melanoma, specializing in situations where superficial spreading, lentigo maligna, and nodular melanoma spreads to other parts of the body. Dr. Michael Postow also leads a team of researchers in developing melanoma treatments for patients, focusing on combination therapies and cellular approaches that can overcome resistance to existing treatments. The team has developed many FDA-approved therapies including one recognized as a major scientific advance by the American Society of Clinical Oncology.
Dr. Michael Postow has authored over 200 peer-reviewed publications and has contributed to widely used oncology resources as an editor or reviewer. He also teaches and mentors young doctors. Dr. Michael Postow is an associate professor of medicine at Weill Cornell Medical College and a special contributing faculty member at Gerstner Sloan Kettering Graduate School. He has received awards such as the 40 Under 40 in Cancer distinction as well as multiple teaching honors.